(31.4%), and men with type 2 DM the lowest (6.9%) [4] .
The occurrence of hyperthyroidism in patients with DM was found to be higher than in general population: Perros et al [4] reported a 1% incidence of hyperthyroidism in cases with DM while in the Whickham survey, the incidence of hyperthyroidism was estimated at 0.3% in the general adult population [1] . Graves' disease and toxic nodular goiter are the most frequent causes of hyperthyroidism [6] .
Thyroid hormones in excess promote hyperglycemia by several mechanisms [6] [7] [8] [9] : increased glucose absorption in the bowel, impaired insulin secretion, accelerated insulin degradation, elevation of glucagon levels, increased hepatic glucose production, insulin resistance and, possibly, hypercathecolaminemia. In other words, in hyperthyroidism there is a high glucose output from the liver and a diminished action of insulin. In untreated Graves' disease, increased proinsulin levels in response to meals and a reduced ratio between C-peptide and proinsulin were observed, suggesting a defect in proinsulin processing [10, 11] .
Undiagnosed thyroid dysfunction may affect metabolic control in patients with DM and even favor the occurrence of ketoacidosis [12, 13] . In some conditions, this association may raise the already increased risk for cardiovascular diseases of these patients [14] .
The purpose of this paper was to analyze the evolution of glycemic control, as well as of other clinic and biologic parameters, in patients with T1DM and hyperthyroidism subjected to antithyroid therapy.
Material and method

Patients
This is a retrospective study that included 37 patients, 35 women (94.6%) and 2 men (5.4%), aged 18 to 58 years, all previously diagnosed with T1DM, who were treated in the Department of Endocrinology of the County Emergency Hospital Timisoara between March 2003 and March 2013 for overt hyperthyroidism. The diagnosis was based on hormonal measurements (TSH, FT 4 ± FT 3 ). The study protocol and procedures were approved by the local Ethics Committee. All the subjects were treated for hyperthyroidism with methimazole and were reassessed after six months, by repeating the hormonal and biochemical tests performed at baseline. We mention that insulin therapy was administered according to the rules of medical practice: all patients received basal-bolus regimen, had frequent blood glucose measurements, and insulin dosage was adjusted according to blood glucose values.
Clinic and laboratory measurements
The following data were retrieved from the medical records of the patients: age, DM duration, height, weight and blood pressure. Body mass index (BMI) was calculated. The following biologic parameters were measured in fasting condition (at least 8 hours after the last meal): TSH, FT 3 , FT 4 , HbA 1c , lipids (total cholesterol, LDL cholesterol -LDLc, HDL cholesterol -HDLc, triglycerides -TG) and glycemia. TSH, FT 3 and FT 4 were assessed using ECLIA (electro-chemiluminescence method) having the following reference range: 0.27 -4.20 µUI/mL for TSH, 3.9 -6.7 pmol/L for FT 3 and 12.0 -22.0 pmol/L for FT 4 . A patient was considered to present overt hyperthyroidism if TSH was suppressed and FT 4 and/or FT 3 increased. In all patients thyroid ultrasonography was performed and in 28 patients (75.7%) TSH-receptor antibodies were determined in order to confirm the diagnosis of Graves' disease.
Statistical analysis
Data were analyzed using SPSS version 17 (SPSS, Chicago, IL) and are presented as means ± standard deviations for continuous, normally distributed variables, medians and interquartile ranges for continuous not-normally distributed values and percentages for categorical parameters. In order to assess the significances of the differences, paired t-test was used for two means of paired series. Continuous variables distributions were tested for normality using D'Agostino-Pearson omnibus test and for homoscedasticity with Levene's test. The interrelation between continuous variables was assessed using correlation and regression analysis; its strength was evaluated using Pearson's correlation coefficient and of which statistical significance was calculated with tvalue rank distribution test. The significance of differences between proportions was assessed using Fisher's exact test. A p value <0.05 was considered statistical significant.
Results
The baseline characteristics of these patients are presented in Table 1 . After six months of therapy, thyroid function became normal in 25 patients (67.6%). For the entire study group, we observed a significant decrease in HbA 1c level (0.41 ± 0.34%; p <0.001) and systolic blood pressure (5.4 ± 7.0 mmHg; p <0.001). Increases were recorded for TG (12.9 ± 14.4 mg/dL; p<0.001), HDLc (2.0 ± 2.4mg/dL; p<0.001), LDLc (5.9 ± 4.9 mg/dL; p<0.001), non-HDLc (8.5 ± 6.2 mg/dL; p <0.001), body weight (2.6 ± 2.2 kg; p = 0.004) and diastolic blood pressure (2.2 ± 3.9 mmHg; p=0.002). Mean blood pressure showed no significant changes (from 98.3± 11.8 to 98.7 ± 12.3mmHg; p = 0.57). The results are shown in Table 2 . After antithyroid treatment, the proportion of patients reaching good glycemic control (HbA 1c <7%) increased significantly, from 10.8% to 35.1% (p=0.025).
The improvement in glucose control was obtained in the conditions of the reduction of the mean daily dose of insulin from 0.83 IU/kg body weight to 0.68 IU/kg body weight.
The analysis on subgroups (patients who became euthyroid after therapy versus patients who remained hyperthyroid) showed a better evolution of glucose control in the first subgroup: HbA 1c presented a more important reduction (0.54 ± 0.29% vs. 0.13 ± 0.28%; p <0.001), and the percentage of patients that reached the target for glycemic control was higher (44% v. 16.7%, p = 0.149). After 6 months of treatment, when compared to hyperthyroid patients, the euthyroid group was associated with a lower HbA1c (7.22% vs. 8.15%, p <0.001) and daily insulin dose (0.61 UI/kg vs. 0.82 UI/kg, p <0.001), higher triglycerides (172.56 mg/dL vs. 128.47 mg/dL, p=0.001) and body weight (60.3 kg vs. 55.7 kg, p<0.001). The differences in the other studied parameters had no statistical significance (Table 3) . (Figure 1) .
Furthermore, the increases in TSH value, obtained after treatment, reverse correlated significantly with the differences in HbA1c (ΔHbA1c = HbA1c after treatment -HbA1c prior treatment), meaning that a more important increase in TSH values leads to a more significant improvement in glycemic control (r= -0.37 [95% CI -0.62 to -0.05], p=0.023) (Figure 2 ). There are many factors that influence the quality of glucose control. Some of them depend on the patient (education, self blood glucose monitoring, compliance to therapy, motivation, Romanian population that is living in a region with adequate iodine intake, as indicated by previous studies, and has an increasing incidence of hyperthyroidism in the last years [23, 24] .
Discussions
In our study, HbA 1c decreased after 6 months of antithyroid therapy, mainly in patients who became euthyroid. There are several explanations for the good evolution of glycemic control. The first one is the therapeutic control of thyroid function that acts by multiple mechanisms, discussed previously. Second, patients with hyperthyroidism have an increased appetite and, in the case of coexistence of DM, this contributes to the glycemic disequilibrium. By compensating the thyroid function, the appetite decreases, fact that presumably contributes to a better glycemic control. However, there are no data regarding the evolution of the caloric intake of our patients during the study. Finally, the compliance to therapy is highly variable. One can assume that patients who became euthyroid under specific treatment might have been more compliant to antithyroid therapy (and insulin regimen, as well) and that could have led to a better glycemic control. All the 37 patients analyzed in this paper had been diagnosed with T1DM before hyperthyroidism and were on a stable therapeutic regimen. Their adherence to the medical recommendations was probably the same before and during the follow-up period. That's why we consider that changes in glycemic control were due mainly to antithyroid therapy.
Our results indicate that correction of hyperthyroidism induced an improvement of glycemic control, in the condition of a reduction in insulin dose, underlined by a significant decrease of HbA 1c (with 0.41%) and an increase in the number of patients that reached the main glycemic target (from 10.8% to 35.1%). This value may seem not clinically relevant, but it is well known that in T1DM patients improvement of HbA 1c has benefits on long term [15] and that it is preferable to obtain a good glycemic control early in the course of the disease, because this influences the occurrence of complications, as well [16] . The reduction of HbA 1c was more important in the subgroup of patients who became euthyroid after 6 months of therapy. Furthermore, the percentage of patients that reached the target for HbA 1c was higher in this group (the differences did not reach the threshold for significance for this parameter due to the relative small number of subjects included in the study).
The negative, statistically significant correlation found between TSH and HbA 1c after hyperthyroidism treatment, confirms the influence of this therapy on the quality of the glycemic control.
After correction of hyperthyroidism, significant changes in some cardiovascular risk factors were noted, leading to changes in the risk profile of the patients: LDLc, non-HDLc, TG, diastolic blood pressure and body weight increased, worsening the cardiovascular prognosis; HDLc augmented and systolic blood pressure decreased, with favorable consequences on cardiovascular profile; mean blood pressure remained, practically, unchanged. Since the therapy with statins and antihypertensive agents has not been modified during the follow-up, the changes of the aforementioned parameters could be explained only by the influence of the thyroid hormones and glycemic control. The increase of the cholesterol fractions (HDLc, non-HDLc and LDLc) was induced mainly by the correction of hyperthyroidism, being known that the thyroid hormones are involved in the metabolism of cholesterol by several mechanisms [25] : they increase the expression of both 3-hydroxy-3-methyl-glutaryl-CoA reductase and LDL receptors. The TG values are influenced by both glycemic control and thyroid function (thyroid hormones activate the enzyme lipoprotein lipase, responsible for the catabolism of TG-rich lipoproteins). In general, they decrease in parallel with the reduction of HbA 1c in patients with DM and increase when hyperthyroidism is compensated under specific therapy. In our patients, the increase in TG could be explained by the more pronounced influence of the improvement of thyroid function than of the glycemic control. The evolution of the overall global risk for cardiovascular diseases is difficult to be evaluated in these circumstances. Even if cardiovascular risk would have increased after antithyroid therapy, the treatment of hyperthyroidism is worth even judged by this perspective: it is known that uncontrolled thyroid function means a higher risk of cardiovascular morbidity and mortality, mainly due to arrhythmias [26, 27] .
Our work has some strengths: it is the first paper that analyses the evolution of the glycemic control under antithyroid therapy in Romanian patients with T1DM and hyperthyroidism; all the patients were treated for DM in a Diabetes Center by highly qualified medical staff; the patients were on a stable therapeutic regimen for DM, so that this did not exert an important influence on the glycemic control once antithyroid therapy was started. There are some limitations, as well: this was a retrospective study; the patients were not followed-up in accordance to a standardized protocol; there is no accurate information regarding the caloric intake and the compliance to antidiabetic and antithyroid therapy; the majority of the patients were women, due to the fact that Graves' disease is much more prevalent in women than in men. The question that remains unanswered after this analysis is related to the possible influence of the diet, in addition to antithyroid treatment, on the improvement of glycemic control.
Conclusions
To conclude, our study confirms that the therapeutic control of increased thyroid function contributes significantly to the improvement of glycemic control and changes the profile of cardiovascular risk factors of the patients. Due to the fact that thyroid dysfunction is quite frequently encountered in T1DM patients and that the correction of hyperthyroidism represents a method for improving glycemic control (in addition to the other known benefits), screening tests for thyroid function should be periodically performed in every patient with T1DM.
